Results of clinical studies with capreomycin, ethambutol and rifampicin in the Heckeshorn Hospital, Berlin.
D000368:Aged; D000636:Aminosalicylic Acids / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001604:Berlin; D002986:Clinical Trials as Topic; D003523:Cycloserine / Q000627:therapeutic use; D004352:Drug Resistance, Microbial; D004977:Ethambutol / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D006996:Hypocalcemia / Q000139:chemically induced; D007008:Hypokalemia / Q000139:chemically induced; D007674:Kidney Diseases / Q000139:chemically induced; D008875:Middle Aged; D012293:Rifampin / Q000009:adverse effects / Q000627:therapeutic use*; D013752:Tetracycline / Q000627:therapeutic use; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy*; D014508:Urea / Q000097:blood; D014786:Vision Disorders / Q000139:chemically induced
D000636:Aminosalicylic Acids; D000900:Anti-Bacterial Agents; D004977:Ethambutol; D014508:Urea; D003523:Cycloserine; D013752:Tetracycline; D012293:Rifampin